Dl‑3‑n‑butylphthalide alleviates cognitive impairment in amyloid precursor protein/presenilin 1 transgenic mice by regulating the striatal‑enriched protein tyrosine phosphatase/ERK/cAMP‑response element‑binding protein signaling pathway Corrigendum in /10.3892/etm.2022.11742

Zhao,Yan; Yang,Wen-Qiang; Yu,Lu; Yang,Jing; Zhu,Hai-Rong; Zhang,Lin

doi:10.3892/etm.2022.11248

Dl‑3‑n‑butylphthalide alleviates cognitive impairment in amyloid precursor protein/presenilin 1 transgenic mice by regulating the striatal‑enriched protein tyrosine phosphatase/ERK/cAMP‑response element‑binding protein signaling pathway

Corrigendum in: /10.3892/etm.2022.11742

Authors:
- Yan Zhao
- Wen-Qiang Yang
- Lu Yu
- Jing Yang
- Hai-Rong Zhu
- Lin Zhang
View Affiliations

Affiliations: Life Science Institution, Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China, Provincial Key Laboratory of Cardiovascular and Cerebrovascular Drug Basic Research, Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China, Department of Neurology, Affiliated Taizhou Hospital of Nanjing University of Chinese Medicine, Taizhou, Jiangsu 225300, P.R. China, Department of Neurology, Affiliated Wenling Hospital of Wenzhou Medical University, Wenling, Zhejiang 317500, P.R. China
Published online on: March 10, 2022 https://doi.org/10.3892/etm.2022.11248
Article Number: 319
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment and the deposition of amyloid plaques in the brain. In a transgenic mouse model of AD, cognitive impairment and synaptic dysfunction were revealed to be associated with soluble amyloid oligomers and to occur prior to plaque formation. The results of our previous studies revealed that striatal‑enriched protein tyrosine phosphatase (STEP)61 negatively regulated the β‑amyloid protein‑mediated ERK/cAMP‑response element‑binding protein (CREB) signaling pathway. Dl‑3‑n‑butylphthalide (NBP) is a synthetic compound approved by the Food and Drug Administration of China for the treatment of ischemic stroke in 2002. Studies have shown that the neuroprotective effects of NBP involve multiple mechanisms. The present study further explored the mechanism of NBP therapy in amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic mice, and the involvement of the STEP/ERK/CREB signaling pathway. The results suggested that NBP treatment effectively ameliorated the spatial learning and memory impairment of the APP/PS1 transgenic mice, which was assessed using a Morris water maze. In addition, NBP reduced amyloid‑induced activation of STEP61 levels, while increasing phosphorylated (p)‑ERK1/2 and p‑CREB levels in the cerebral cortex and hippocampus of APP/PS1 transgenic mice by western blotting and immunostaining. In conclusion, the present study provided evidence to suggest that the new drug NBP improved amyloid‑induced learning and memory deficits, likely through the regulation of the STEP/ERK/CREB pathway. The results revealed that NBP, as a multi‑target drug, may exert a neuroprotective effect. Therefore, NBP may serve as an effective treatment for AD.

View Figures

View References

1	Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA and Cummings JL: Alzheimer's disease. Nat Rev Dis Primers. 1(15056)2015.PubMed/NCBI View Article : Google Scholar
2	Hardy JA and Higgins GA: Alzheimer's disease: The amyloid cascade hypothesis. Science. 256:184–185. 1992.PubMed/NCBI View Article : Google Scholar
3	Wang X, Perumalsamy H, Kwon HW, Na YE and Ahn YJ: Effects and possible mechanisms of action of acacetin on the behavior and eye morphology of Drosophila models of Alzheimer's disease. Sci Rep. 5(16127)2015.PubMed/NCBI View Article : Google Scholar
4	Tao CC, Cheng KM, Ma YL, Hsu WL, Chen YC, Fuh JL, Lee WJ, Chao CC and Lee EHY: Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer's disease. Cell Death Differ. 27:192–209. 2020.PubMed/NCBI View Article : Google Scholar
5	De S, Whiten DR, Ruggeri FS, Hughes C, Rodrigues M, Sideris DI, Taylor CG, Aprile FA, Muyldermans S, Knowles TPJ, et al: Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. Acta Neuropathol Commun. 7(120)2019.PubMed/NCBI View Article : Google Scholar
6	Gu X, Wu H, Xie Y, Xu L, Liu X and Wang W: Caspase-1/IL-1β represses membrane transport of GluA1 by inhibiting the interaction between Stargazin and GluA1 in Alzheimer's disease. Mol Med. 27(8)2021.PubMed/NCBI View Article : Google Scholar
7	Wang S, Ma F, Huang L, Zhang Y and Peng Y, Xing C, Feng Y, Wang X and Peng Y: Dl-3-n-butylphthalide (NBP): A promising therapeutic agent for ischemic stroke. CNS Neurol Disord Drug Targets. 17:338–347. 2018.PubMed/NCBI View Article : Google Scholar
8	Cheng X, Wang H, Liu C, Zhong S, Niu X, Zhang X, Qi R, Zhao S, Zhang X, Qu H and Zhao C: Dl-3-n-butylphthalide promotes remyelination process in cerebral white matter in rats subjected to ischemic stroke. Brain Res. 1717:167–175. 2019.PubMed/NCBI View Article : Google Scholar
9	Chong ZZ and Feng YP: DI-3-n-butylphthalide improves regional cerebral blood flow after experimental subarachnoid hemorrhage in rats. Zhongguo Yao Li Xue Bao. 20:509–512. 1999.PubMed/NCBI
10	Wu F, Xu K, Xu K, Teng C, Zhang M, Xia L, Zhang K, Liu L, Chen Z, Xiao J, et al: Dl-3n-butylphthalide improves traumatic brain injury recovery via inhibiting autophagy-induced blood-brain barrier disruption and cell apoptosis. J Cell Mol Med. 24:1220–1232. 2020.PubMed/NCBI View Article : Google Scholar
11	Xiong Z, Lu W, Zhu L, Zeng L, Shi C, Jing Z, Xiang Y, Li W, Tsang CK, Ruan Y and Huang L: Dl-3-n-butylphthalide treatment enhances hemodynamics and ameliorates memory deficits in rats with chronic cerebral hypoperfusion. Front Aging Neurosci. 9(238)2017.PubMed/NCBI View Article : Google Scholar
12	Lv C, Ma Q, Han B, Li J, Geng Y, Zhang X and Wang M: Long-term DL-3-n-butylphthalide treatment alleviates cognitive impairment correlate with improving synaptic plasticity in SAMP8 mice. Front Aging Neurosci. 10(200)2018.PubMed/NCBI View Article : Google Scholar
13	Chen XQ, Qiu K, Liu H, He Q, Bai JH and Lu W: Application and prospects of butylphthalide for the treatment of neurologic diseases. Chin Med J (Engl). 132:1467–1477. 2019.PubMed/NCBI View Article : Google Scholar
14	Liu CY, Zhao ZH, Chen ZT, Che CH, Zou ZY, Wu XM, Chen SG, Li YX, Lin HB, Wei XF, et al: DL-3-n-butylphthalide protects endothelial cells against advanced glycation end product-induced injury by attenuating oxidative stress and inflammation responses. Exp Ther Med. 14:2241–2248. 2017.PubMed/NCBI View Article : Google Scholar
15	Wang G, Zhang J, Hu X, Zhang L, Mao L, Jiang X, Liou AK, Leak RK, Gao Y and Chen J: Microglia/macrophage polarization dynamics in white matter after traumatic brain injury. J Cereb Blood Flow Metab. 33:1864–1874. 2013.PubMed/NCBI View Article : Google Scholar
16	Liao D, Xiang D, Dang R, Xu P, Wang J, Han W, Fu Y, Yao D, Cao L and Jiang P: Neuroprotective effects of dl-3-n-butylphthalide against doxorubicin-induced neuroinflammation, oxidative stress, endoplasmic reticulum stress, and behavioral changes. Oxid Med Cell Longev. 2018(9125601)2018.PubMed/NCBI View Article : Google Scholar
17	He RJ, Yu ZH, Zhang RY and Zhang ZY: Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol Sin. 35:1227–1246. 2014.PubMed/NCBI View Article : Google Scholar
18	Jang SS, Royston SE, Lee G, Wang S and Chung HJ: Seizure-induced regulations of amyloid-β, STEP61, and STEP61 substrates involved in hippocampal synaptic plasticity. Neural Plast. 2016(2123748)2016.PubMed/NCBI View Article : Google Scholar
19	Zhang L, Xie JW, Yang J and Cao YP: Tyrosine phosphatase STEP61 negatively regulates amyloid β-mediated ERK/CREB signaling pathways via α7 nicotinic acetylcholine receptors. J Neurosci Res. 91:1581–1590. 2013.PubMed/NCBI View Article : Google Scholar
20	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th edition. National Academies Press, Washington, DC, 2011.
21	Zhuang XX, Zang X, Zheng GY, Hua N, Sun Y, Hu YH and He L: Polyprenols mitigate cognitive dysfunction and neuropathology in the APP/PS1 mouse. Phytother Res. 32:1098–1107. 2018.PubMed/NCBI View Article : Google Scholar
22	Poddar R, Rajagopal S, Shuttleworth CW and Paul S: Zn2+-dependent activation of the Trk signaling pathway induces phosphorylation of the brain-enriched tyrosine phosphatase STEP: Molecular basis for ZN2+-induced ERK MAPK activation. J Biol Chem. 291:813–825. 2016.PubMed/NCBI View Article : Google Scholar
23	Goebel-Goody SM, Baum M, Paspalas CD, Fernandez SM, Carty NC, Kurup P and Lombroso PJ: Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol Rev. 64:65–87. 2012.PubMed/NCBI View Article : Google Scholar
24	Paul S, Nairn AC, Wang P and Lombroso PJ: NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat Neurosci. 6:34–42. 2003.PubMed/NCBI View Article : Google Scholar
25	Lugo JN, Brewster AL, Spencer CM and Anderson AE: Kv4.2 knockout mice have hippocampal-dependent learning and memory deficits. Learn Mem. 19:182–189. 2012.PubMed/NCBI View Article : Google Scholar
26	Owona BA, Zug C, Schluesener HJ and Zhang ZY: Amelioration of behavioral impairments and neuropathology by antiepileptic drug topiramate in a transgenic Alzheimer's disease model mice, APP/PS1. Int J Mol Sci. 20(3003)2019.PubMed/NCBI View Article : Google Scholar
27	Huang P, Yang YH, Chang YH, Chang SL, Chou MC, Lai CL, Liu CK and Chen HY: Association of early-onset Alzheimer's disease with germline-generated high affinity self-antigen load. Transl Psychiatry. 10(146)2020.PubMed/NCBI View Article : Google Scholar
28	Bush AI and Tanzi RE: Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics. 5:421–432. 2008.PubMed/NCBI View Article : Google Scholar
29	Kamceva M, Benedict J, Nairn AC and Lombroso PJ: Role of striatal-enriched tyrosine phosphatase in neuronal function. Neural Plast. 2016(8136925)2016.PubMed/NCBI View Article : Google Scholar
30	Huang L, Lan J, Tang J, Kang Y, Feng X, Wu L and Peng Y: L-3-n-butylphthalide improves synaptic and dendritic spine plasticity and ameliorates neurite pathology in Alzheimer's disease mouse model and cultured hippocampal neurons. Mol Neurobiol. 58:1260–1274. 2021.PubMed/NCBI View Article : Google Scholar
31	Zhang Y, Huang LJ, Shi S, Xu SF, Wang XL and Peng Y: L-3-n-butylphthalide rescues hippocampal synaptic failure and attenuates neuropathology in aged APP/PS1 mouse model of Alzheimer's disease. CNS Neurosci Ther. 22:979–987. 2016.PubMed/NCBI View Article : Google Scholar